Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Aβ-positive cohort's demographics and biomarker levels

From: CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response

 

Mutation carriers

Non-carriers AD

All

PTC carriersa

VNTR expansion carriersa

Samples (n)

 Aβ+

36

23

13

127

 AAO

72.9 (10.3)

71.3 (10.9)

75.8 (8.7)

75.6 (8.1)

Sex

 Male

14 (38.9%)

10 (43.5%)

4 (30.8%)

45 (35.4%)

 Female

22 (61.1%)

13 (56.5%)

9 (69.2%)

82 (64.6%)

APOE ε4

 Positive

24 (66.7%)

16 (69.6%)

8 (61.5%)

75 (59.1%)

 Negative

12 (33.3%)

7 (30.4%)

5 (38.5%)

52 (40.9%)

Biomarkers (n)

 Aβ1–42 (pg/mL)

490.5 (273.3)

535 (345.5)

385 (228)

578 (308)

 Aβ1–40 (pg/mL)

5957.5 (3734.3)

6638 (4086.5)

4405 (1431)

6738 (3088.5)

 Aβ ratio

0.089 (0.033)

0.081 (0.026)

0.09 (0.04)

0.09 (0.03)

 sAPPα (ng/mL)

97.5 (66.3)

119 (85.5)

83 (27)

113.5 (74.8) (n = 126)

 sAPPβ (ng/mL)

93.5 (72.5)

110 (84.5)

82 (20)

117 (83)

 YKL-40 (ng/mL)

187 (90)

208 (80)

150 (45)

201 (112.5)

 hFABP (ng/mL)

4.39 (2.8)

4.86 (2.37)

3.2 (2.9)

4 (1.8) (n = 126)

 T-tau (pg/mL)

619 (544) (n = 29)

723 (386) (n = 17)

464 (475.5) (n = 12)

548 (428) (n = 112)

 P-tau181 (pg/mL)

70 (53) (n = 29)

76 (45) (n = 17)

60.5 (57.8) (n = 12)

81 (47.5) (n = 111)

  1. Demographics are presented as mean (SD) or mean (%). Non-parametric biomarker levels are presented as median (interquartile range). If biomarker data was not available for the entire subgroup, the number of samples included is shown
  2. aOne sample had both a PTC mutation and VNTR expansion and was included in both subgroups
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193